title: [Study of the humoral immune suppression of recombinant human collagen type II peptide 250-270].
abstract: OBJECTIVE
  To investigate the modulation of rhC II 250-270 peptide on special humoral immune response in the course of oral administration.
  
  
  METHODS
  ELISA was used to determine antigen-specific antibodies in mice sera. The frequency of anti-C II and anti-C II (250-270) antibody-forming spleen cells was measured by ELISPOT.
  
  
  RESULTS
  The level of C II- and C II (250-270)- specific IgG in serum from the mice fed with rhC II (250-270) were (0.82+/-0.02) and (0.84+/-0.04) respectively, and lower significantly than those of collagen-induced arthritis (CIA) control group. The anti-C II (250-270) antibody responses were suppressed obviously (P<0.01). The frequency of antibody-forming cells in the spleen from rhC II (250-270)-fed mice were (158+/-9 counts/well) and (181+/-10 counts/well) respectively, and also were reduced significantly when compared with that in CIA control group (247+/-16 counts/well)(P<0.05).
  
  
  CONCLUSIONS
  Oral rhC II (250-270) could induce specific suppression of humoral responds in CIA. These findings together with a better understanding of the mechanisms of oral tolerance and regulation of humoral immune response in CIA, will help the development of innovative therapeutic intervention for rheumatoid arthritis.
authors.affiliation: Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
authors.forename: Hong-Kun
authors.initials: HK
authors.lastname: Wang
authors.forename: Ping
authors.initials: P
authors.lastname: Zhu
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Li
authors.forename: Zhao-Hui
authors.initials: ZH
authors.lastname: Zheng
authors.forename: Jun-Feng
authors.initials: JF
authors.lastname: Jia
authors.forename: Jin
authors.initials: J
authors.lastname: Ding
authors.forename: Chun-Mei
authors.initials: CM
authors.lastname: Fan
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D000918:Antibody Specificity; D001169:Arthritis, Experimental / Q000276:immunology / Q000473:pathology; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy; D024043:Collagen Type II / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007165:Immunosuppression Therapy; D008297:Male; D051379:Mice; D010446:Peptide Fragments / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D013154:Spleen / Q000276:immunology / Q000473:pathology
chemical_list: D024043:Collagen Type II; D010446:Peptide Fragments; D011994:Recombinant Proteins